IgA Nephropathy: Emerging Mechanisms of Disease

被引：4

作者：

Roberts, Lydia E. ^{[1
,2
,3
]}

Williams, Chloe E. C. ^{[4
,5
]}

Oni, Louise ^{[5
,6
]}

Barratt, Jonathan ^{[1
,2
,3
]}

Selvaskandan, Haresh ^{[1
,2
,3
]}

机构：

[1] Univ Hosp Leicester NHS Trust, John Walls Renal Unit, Leicester, England

[2] Univ Leicester, Leicester, England

[3] Univ Leicester, Dept Cardiovasc Sci, Leicester, England

[4] Royal Liverpool & Broadgreen Univ Hosp Trusts, Liverpool, England

[5] Univ Liverpool, Inst Life Course & Med Sci, Dept Womens & Childrens Hlth, Liverpool, England

[6] Alder Hey Childrens NHS Fdn Trust Hosp, Dept Paediat Nephrol, Liverpool, England

来源：

INDIAN JOURNAL OF NEPHROLOGY | 2024年 / 34卷 / 04期

关键词：

Four-hit hypothesis; IgA nephropathy; inflammation; pathogenesis; treatments; FECAL MICROBIOTA TRANSPLANTATION; GENOME-WIDE ASSOCIATION; SPLEEN TYROSINE KINASE; LONG-TERM OUTCOMES; IMMUNE-COMPLEXES; ENDOTHELIN RECEPTOR; ALTERNATIVE PATHWAY; GLOMERULAR DEPOSITS; EPITHELIAL-CELLS; O-GLYCOSYLATION;

D O I：

10.25259/ijn_425_23

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis reported across the world and is characterized by immunoglobulin A (IgA) dominant mesangial deposits, which are poorly O-glycosylated. This deposition leads to a cascade of glomerular and tubulointerstitial inflammation and fibrosis, which can progress to chronic kidney disease. The variability in rate of progression reflects the many genetic and environmental factors that drive IgAN. Here, we summarize the contemporary understanding of the disease mechanisms that drive IgAN and provide an overview of new and emerging therapies, which target these mechanisms.

引用

页码：297 / 309

页数：13

共 150 条

[1] Evaluating a New International Risk-Prediction Tool in IgA Nephropathy [J].

Barbour, Sean J. ;

Coppo, Rosanna ;

Zhang, Hong ;

Liu, Zhi-Hong ;

Suzuki, Yusuke ;

Matsuzaki, Keiichi ;

Katafuchi, Ritsuko ;

Er, Lee ;

Espino-Hernandez, Gabriela ;

Kim, S. Joseph ;

Reich, Heather N. ;

Feehally, John ;

Cattran, Daniel C. ;

Russo, M. L. ;

Troyanov, S. ;

Cook, H. T. ;

Roberts, I. ;

Tesar, V. ;

Maixnerova, D. ;

Lundberg, S. ;

Gesualdo, L. ;

Emma, F. ;

Fuiano, L. ;

Beltrame, G. ;

Rollino, C. ;

Amore, A. ;

Camilla, R. ;

Peruzzi, L. ;

Praga, M. ;

Feriozzi, S. ;

Polci, R. ;

Segoloni, G. ;

Colla, L. ;

Pani, A. ;

Piras, D. ;

Angioi, A. ;

Cancarini, G. ;

Ravera, S. ;

Durlik, M. ;

Moggia, E. ;

Ballarin, J. ;

Di Giulio, S. ;

Pugliese, F. ;

Serriello, I. ;

Caliskan, Y. ;

Sever, M. ;

Kilicaslan, I. ;

Locatelli, F. ;

Del Vecchio, L. ;

Wetzels, J. F. M. .

JAMA INTERNAL MEDICINE, 2019, 179 (07) :942-952

[2] Individuals of Pacific Asian origin with IgA nephropathy have an increased risk of progression to end-stage renal disease [J].

Barbour, Sean J. ;

Cattran, Daniel C. ;

Kim, S. Joseph ;

Levin, Adeera ;

Wald, Ron ;

Hladunewich, Michelle A. ;

Reich, Heather N. .

KIDNEY INTERNATIONAL, 2013, 84 (05) :1017-1024

[3] Exaggerated systemic antibody response to mucosal Helicobacter pylori infection in IgA nephropathy [J].

Barratt, J ;

Bailey, EM ;

Buck, KS ;

Mailley, J ;

Moayyedi, P ;

Feehally, J ;

Turney, JH ;

Crabtree, JE ;

Allen, AC .

AMERICAN JOURNAL OF KIDNEY DISEASES, 1999, 33 (06) :1049-1057

[4]

Barratt J., 2021, Kidney International Reports, DOI DOI 10.1016/J.EKIR.2021.03.868

[5]

Barratt J., 2022, KIDNEY INT REP, V7, pS45

[6]

Barratt J., 2022, Kidney Int. Rep, V7, pS46, DOI [10.1016/j.ekir.2022.01.121, DOI 10.1016/J.EKIR.2022.01.121]

[7]

Barratt J., 2022, KIDNEY INT REP, V7, pS236, DOI [10.1016/j.ekir.2022.01.577, DOI 10.1016/J.EKIR.2022.01.577]

[8] Immunopathogenesis of IgAN [J].

Barratt, Jonathan ;

Smith, Alice C. ;

Molyneux, Karen ;

Feehally, John .

SEMINARS IN IMMUNOPATHOLOGY, 2007, 29 (04) :427-443

[9] Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy [J].

Barratt, Jonathan ;

Lafayette, Richard ;

Kristensen, Jens ;

Stone, Andrew ;

Cattran, Daniel ;

Floege, Jurgen ;

Tesar, Vladimir ;

Trimarchi, Hernan ;

Zhang, Hong ;

Eren, Necmi ;

Paliege, Alexander ;

Rovin, Brad H. .

KIDNEY INTERNATIONAL, 2023, 103 (02) :391-402

[10] Randomized Phase II JANUS Study of Atacicept in Patients With IgA Nephropathy and Persistent Proteinuria [J].

Barratt, Jonathan ;

Tumlin, James ;

Suzuki, Yusuke ;

Kao, Amy ;

Aydemir, Aida ;

Pudota, Kishore ;

Jin, Hulin ;

Guehring, Hans ;

Appel, Gerald .

KIDNEY INTERNATIONAL REPORTS, 2022, 7 (08) :1831-1841

← 1 2 3 4 5 6 7 8 9 10 →